VIRALEZE COVID-19 nasal spray study to commence in January
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
- SPL7013 shows potent antiviral activity in RSV
- Completion of Placement and SPP raises $48.9M in total
- Starpharma receives $5.7M R&D tax incentive refund
- Share Purchase Plan offer document
Later from Starpharma
- Change in substantial holding
- AZD0466 clinical DEP program global expansion
- Starpharma signs DEP ADC Research Agreement with MSD
- VIRALEZE antiviral nasal spray registered in Europe
- DEP HER2-lutetium outperforms in human breast cancer model
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma